Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
Abstract
The efficacy of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is primarily ascribed as a source of neutralizing anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. However, the composition of other immune components in CCP and their potential roles remain largely unexplored. This study aimed to describe the composition and concentrations of plasma cytokines and chemokines in eligible CCP donors.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 26, 2020
- Source ID
- 10.1093/ofid/ofaa574
Entities
People
- Aaron Tobian
- Alison G Abraham
- Andrew D. Redd
- Andrew Pekosz
- Arturo Casadevall
- David P Sullivan
- Eshan U Patel
- Evan M Bloch
- Kirsten Littlefield
- M. Kate Grabowski
- Oliver Laeyendecker
- Ruchee Shrestha
- Sarah E. Benner
- Shmuel Shoham
- Tania S. Bonny
- Thomas C. Quinn
- Xianming Zhu
Organizations
- Bloomberg Philanthropies
- Johns Hopkins Bloomberg School of Public Health
- Johns Hopkins School of Medicine
- Johns Hopkins University
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- United States Department of Defense
- University of Colorado